调节表皮生长因子受体失活的分子机制。

Clinical medicine. Oncology Pub Date : 2008-01-01 Epub Date: 2008-02-09 DOI:10.4137/cmo.s498
Brian P Ceresa, Phillip A Vanlandingham
{"title":"调节表皮生长因子受体失活的分子机制。","authors":"Brian P Ceresa,&nbsp;Phillip A Vanlandingham","doi":"10.4137/cmo.s498","DOIUrl":null,"url":null,"abstract":"<p><p>The Epidermal Growth Factor Receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK). These cell surface receptors are integral membrane proteins that bind ligands on their extracellular domain and relay that information to within the cell. The activated EGFR regulates diverse cell fates such as growth, proliferation, differentiation, migration, and apoptosis. These signaling properties are important for the appropriate development and maintenance of an organism. However, when inappropriately controlled, due to EGFR overexpression or hyperactivation, these signaling events are characteristic of many cancers. It remains unclear whether the uncontrolled EGFR activity leads to cell transformation or is a consequence of cell transformation. Regardless of the cause, increased EGFR activity serves both as a biomarker in the diagnosis of some cancers and is a molecular target for anti-cancer therapies. The promising results with current anti-EGFR therapies suggest that the receptor is a viable molecular target for a limited number of applications. However, to become an effective therapeutic target for other cancers that have elevated levels of EGFR activity, current approaches for inhibiting EGFR signaling will need to be refined. Here we describe the molecular mechanisms that regulate EGFR inactivation and discuss their potential as therapeutic targets for inhibiting EGFR signaling.</p>","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"47-61"},"PeriodicalIF":0.0000,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/cmo.s498","citationCount":"11","resultStr":"{\"title\":\"Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation.\",\"authors\":\"Brian P Ceresa,&nbsp;Phillip A Vanlandingham\",\"doi\":\"10.4137/cmo.s498\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The Epidermal Growth Factor Receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK). These cell surface receptors are integral membrane proteins that bind ligands on their extracellular domain and relay that information to within the cell. The activated EGFR regulates diverse cell fates such as growth, proliferation, differentiation, migration, and apoptosis. These signaling properties are important for the appropriate development and maintenance of an organism. However, when inappropriately controlled, due to EGFR overexpression or hyperactivation, these signaling events are characteristic of many cancers. It remains unclear whether the uncontrolled EGFR activity leads to cell transformation or is a consequence of cell transformation. Regardless of the cause, increased EGFR activity serves both as a biomarker in the diagnosis of some cancers and is a molecular target for anti-cancer therapies. The promising results with current anti-EGFR therapies suggest that the receptor is a viable molecular target for a limited number of applications. However, to become an effective therapeutic target for other cancers that have elevated levels of EGFR activity, current approaches for inhibiting EGFR signaling will need to be refined. Here we describe the molecular mechanisms that regulate EGFR inactivation and discuss their potential as therapeutic targets for inhibiting EGFR signaling.</p>\",\"PeriodicalId\":88451,\"journal\":{\"name\":\"Clinical medicine. Oncology\",\"volume\":\"2 \",\"pages\":\"47-61\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4137/cmo.s498\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical medicine. Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4137/cmo.s498\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2008/2/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical medicine. Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/cmo.s498","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2008/2/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

摘要

表皮生长因子受体(EGFR)是酪氨酸激酶(RTK)的典型受体。这些细胞表面受体是完整的膜蛋白,与细胞外结构域的配体结合,并将信息传递到细胞内。激活的EGFR调节多种细胞命运,如生长、增殖、分化、迁移和凋亡。这些信号特性对于生物体的正常发育和维持是重要的。然而,当由于EGFR过度表达或过度激活而控制不当时,这些信号事件是许多癌症的特征。目前尚不清楚不受控制的EGFR活性是导致细胞转化还是细胞转化的结果。不管原因是什么,EGFR活性的增加既是诊断某些癌症的生物标志物,也是抗癌治疗的分子靶点。目前抗egfr治疗的令人鼓舞的结果表明,受体是一个可行的分子靶点,用于有限数量的应用。然而,为了成为其他EGFR活性水平升高的癌症的有效治疗靶点,目前抑制EGFR信号传导的方法需要改进。在这里,我们描述了调节EGFR失活的分子机制,并讨论了它们作为抑制EGFR信号传导的治疗靶点的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation.

Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation.

Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation.

The Epidermal Growth Factor Receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK). These cell surface receptors are integral membrane proteins that bind ligands on their extracellular domain and relay that information to within the cell. The activated EGFR regulates diverse cell fates such as growth, proliferation, differentiation, migration, and apoptosis. These signaling properties are important for the appropriate development and maintenance of an organism. However, when inappropriately controlled, due to EGFR overexpression or hyperactivation, these signaling events are characteristic of many cancers. It remains unclear whether the uncontrolled EGFR activity leads to cell transformation or is a consequence of cell transformation. Regardless of the cause, increased EGFR activity serves both as a biomarker in the diagnosis of some cancers and is a molecular target for anti-cancer therapies. The promising results with current anti-EGFR therapies suggest that the receptor is a viable molecular target for a limited number of applications. However, to become an effective therapeutic target for other cancers that have elevated levels of EGFR activity, current approaches for inhibiting EGFR signaling will need to be refined. Here we describe the molecular mechanisms that regulate EGFR inactivation and discuss their potential as therapeutic targets for inhibiting EGFR signaling.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信